Bcl-2 antisense therapy in B-cell malignancies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bcl-2 antisense therapy in B-cell malignancies

Published:2005-07 Issue:4 Volume:19 Page:213-221
ISSN:0268-960X
Container-title:Blood Reviews
language:en
Short-container-title:Blood Reviews

Author:

CHANANKHAN A

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resveratrol induces AMPK and mTOR signaling inhibition-mediated autophagy and apoptosis in multiple myeloma cells;Acta Biochimica et Biophysica Sinica;2021-04-23

2. Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia;Successful Drug Discovery;2018-04-16

3. Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment;Blood Cancer Journal;2017-05

4. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment;British Journal of Haematology;2017-04-27

5. Nanoparticle-based strategy for personalized B-cell lymphoma therapy;International Journal of Nanomedicine;2016-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3